Page last updated: 2024-09-03

ne 58051 and Bone Loss, Osteoclastic

ne 58051 has been researched along with Bone Loss, Osteoclastic in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM1
Martin, MB; Oldfield, E; Szabo, CM1
Clézardin, P; Ebetino, FH; Fournier, PG; Stresing, V1

Other Studies

3 other study(ies) available for ne 58051 and Bone Loss, Osteoclastic

ArticleYear
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
    Journal of medicinal chemistry, 2002, May-23, Volume: 45, Issue:11

    Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins

2002
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
    Journal of medicinal chemistry, 2002, Jul-04, Volume: 45, Issue:14

    Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats

2002
How do bisphosphonates inhibit bone metastasis in vivo?
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:7

    Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Etidronic Acid; Female; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Pyridines; Risedronic Acid; Xenograft Model Antitumor Assays

2010